Inimmune Corporation

12:45 PM - 1:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
Inimmune is a fast-moving innovative biotechnology company focused on the discovery and development of novel immunotherapeutics for allergy, autoimmunity, infectious disease and cancer. Inimmune has a deep pipeline of early and late pre-clinical assets and a strong intellectual property position poised to change the landscape of immunotherapy. The Inimmune team of industry professionals has an average of >15 years of biotech/pharmaceutical experience and a long track record of success in bringing new vaccine adjuvants and immunotherapeutics to the marketplace. The Inimmune management team is actively seeking partnerships and investors who share our vision to create and develop new safe and effective immunotherapeutics for the treatment of allergy, autoimmunity, infectious disease, and cancer.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
INI-4001, INI-2004
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
Chief Scientific and Strategy Officer
Inimmune Corporation